Long term assessment of TK clinical benefit presented at ASH

Milan , 10 December 2012 MolMed S.p.A. announces the presentation of the long term clinical benefit and safety data of its investigational cell-based therapy TK at the 54th Annual Meeting of the American Society of Hematology , taking place in Atlanta .

http://www.drugs.com/clinical_trials/long-term-assessment-tk-clinical-benefit-presented-ash-14814.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29